Pembrolizumab in Relapsed and Refractory Mycosis Fungoides and Sézary Syndrome: A Multicenter Phase II Study
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
PURPOSE: To assess the efficacy of pembrolizumab in patients with advanced relapsed or refractory mycosis fungoides (MF) or Sézary syndrome (SS). PATIENTS AND METHODS: CITN-10 is a single-arm, multicenter phase II trial of 24 patients with advanced MF or SS. Patients were treated with pembrolizumab 2 mg/kg every 3 weeks for up to 24 months. The primary end point was overall response rate by consensus global response criteria. RESULTS: Patients had advanced-stage disease (23 of 24 with stage IIB to IV MF/SS) and were heavily pretreated with a median of four prior systemic therapies. The overall response rate was 38% with two complete responses and seven partial responses. Of the nine responding patients, six had 90% or more improvement in skin disease by modified Severity Weighted Assessment Tool, and eight had ongoing responses at last follow-up. The median duration of response was not reached, with a median response follow-up time of 58 weeks. Immune-related adverse events led to treatment discontinuation in four patients. A transient worsening of erythroderma and pruritus occurred in 53% of patients with SS. This cutaneous flare reaction did not result in treatment discontinuation for any patient. The flare reaction correlated with high PD-1 expression on Sézary cells but did not associate with subsequent clinical responses or lack of response. Treatment responses did not correlate with expression of PD-L1, total mutation burden, or an interferon-γ gene expression signature. CONCLUSION: Pembrolizumab demonstrated significant antitumor activity with durable responses and a favorable safety profile in patients with advanced MF/SS.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade
Ayers, M., Lunceford, J., Nebozhyn, M., Murphy, E., Loboda, A., Kaufman, D. R., Albright, A., Cheng, J. D., Kang, S. P., Shankaran, V., et al. (2017) · Journal of Clinical Investigation · doi:10.1172/jci91190 · Cited by 3,788
Self-citationLesokhin, A. M., Ansell, S. M., Armand, P., Scott, E. C., Halwani, A., Gutierrez, M., Millenson, M. M., Cohen, A. D., Schuster, S. J., Lebovic, D., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.65.9789 · Cited by 1,001 · cited 3×
“Despite its frequent expression, monoallelic and biallelic copy number loss of PD-1 has been reported in CTCLs.12-14 Genomic alterations also have been observed in MF/ SS that involve the PD-1 ligands PD-L115 and PD-L2.”
BackgroundInfluentialDuvic, M., Hymes, K., Heald, P., Breneman, D., Martin, A. G., Myskowski, P., Crowley, C., Yocum, R. C., & for Members of the Bexarotene Worldwide Study Group (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.9.2456 · Cited by 706
Subrahmanyam, P. B., Dong, Z., Gusenleitner, D., Giobbie-Hurder, A., Severgnini, M., Zhou, J., Manos, M., Eastman, L. M., Maecker, H. T., & Hodi, F. S. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0328-8 · Cited by 190 · cited 1×
“CyTOF (Fluidigm, South San Francisco, CA) analysis was performed on Ficoll gradient–purified, cryopreserved PBMCs collected before pembrolizumab treatment from 22 patients as previously described.(26,27) Forty parameters were collected, including a panel of 36 antibodies (Data Supplement).”
MethodSelf-citation
Cited by
Targeting immune checkpoints in hematological malignancies
Salik, B., Smyth, M. J., & Nakamura, K. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00947-6 · Cited by 113
Doeleman, T., Hondelink, L. M., Vermeer, M. H., van Dijk, M. R., & Schrader, A. M. R. (2023) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2023.06.004 · Cited by 26
Jiang, T. T., Kruglov, O., Lin, G. H. Y., Minic, A., Jordan, K., Uger, R. A., Wong, M., Shou, Y., & Akilov, O. E. (2021) · Cancers · doi:10.3390/cancers13235982 · Cited by 12
“A phase II trial using the PD-1 inhibitor pembrolizumab demonstrated an ~8% complete response and a 30% partial response in MF patients, with approximately half of the patients with advanced-stage disease experiencing a transient worsening of their symptoms [4].”
Method
Metadata
- Authors
- Khodadoust, M. S., Rook, A. H., Porcu, P., Foss, F., Moskowitz, A. J., Shustov, A., Shanbhag, S., Sokol, L., Fling, S. P., Ramchurren, N., Pierce, R., Davis, A., Shine, R., Li, S., Fong, S., Kim, J., Yang, Y., Blumenschein, W. M., Yearley, J. H., Das, B., Patidar, R., Datta, V., Cantu, E., McCutcheon, J. N., Karlovich, C., Williams, P. M., Subrahmanyam, P. B., Maecker, H. T., Horwitz, S. M., Sharon, E., Kohrt, H. E., Cheever, M. A., & Kim, Y. H.
- Venue
- Journal of Clinical Oncology
- Published
- 2020-01-01
- Volume
- 38
- Issue
- 1
- Pages
- 20-28
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2974710297
- Cited by
- 237
- References
- 4
- FWCI
- 24.67
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.